消息面上，近期，据凯莱英官微消息，公司旗下凯莱英生物的上海奉贤商业化生产基地正式投产，该基 地是凯莱英生物继上海金山基地和张江科学技术中心后重点打造的又一核心商业化产业基地，可助力客 户快速推进商业化生产。奉贤基地商业化投产意味着凯莱英生物在生物药CDMO领域实现跨越式升级。 据介绍，奉贤基地规划总建筑面积超过13万平方米，重点布局以ADC为代表的偶联药物NDCs(Novel Drug Conjugates)、抗体/TCE、重组蛋白等生物药领域。抗体商业化产能(I期A阶段)采用先进的自动化 系统和生产设备，配备 200L/500L/2000L 一次性生物反应器生产线、20㎡冻干机，可承接IND及商业化 后期项目。NDCs商业化产能(I期B阶段)预计于2026年1月进行商业化投产，配备100L-200L-500L偶联反 应器和10㎡+15㎡+2x20㎡冻干机，可迅捷灵活的满足客户生产需求。 凯莱英(06821)午前涨近3%，截至发稿，涨2.05%，报79.65港元，成交额1551.75万港元。 ...

Core Viewpoint - Kailaiying's subsidiary, Kailaiying Biotech, has officially launched its commercial production base in Shanghai Fengxian, marking a significant upgrade in the biopharmaceutical CDMO sector [1] Group 1: Company Developments - The Fengxian base is the third major commercial production facility following the Jinshan base and Zhangjiang Science and Technology Center, aimed at accelerating clients' commercial production [1] - The total planned construction area of the Fengxian base exceeds 130,000 square meters, focusing on biopharmaceuticals such as ADCs, antibody/TCEs, and recombinant proteins [1] Group 2: Production Capacity - The antibody commercial production capacity (Phase I A) utilizes advanced automation systems and production equipment, featuring production lines with 200L/500L/2000L single-use bioreactors and a 20㎡ freeze-dryer, capable of handling IND and late-stage commercial projects [1] - The NDCs commercial production capacity (Phase I B) is expected to commence in January 2026, equipped with 100L-200L-500L conjugation reactors and multiple freeze-dryers, designed to flexibly meet client production needs [1]